Aethlon Medical

Revenue is zero and development timelines depend on enrollment, safety, and efficacy readouts. TTM operating cash flows are negative and vary with trial pace.

The oncology study in Australia advanced to Cohort 3 with no device‑related SAEs noted so far, which is encouraging for feasibility, but clinical efficacy and regulatory timelines remain highly uncertain. Geographic concentration of operations and reliance on external suppliers add variability.